TY - JOUR
T1 - Population-level effects of human papillomavirus vaccination programs on infections with nonvaccine genotypes
AU - Mesher, David
AU - Soldan, Katherine
AU - Lehtinen, Matti
AU - Beddows, Simon
AU - Brisson, Marc
AU - Brotherton, Julia M.L.
AU - Chow, Eric P.F.
AU - Cummings, Teresa
AU - Drolet, Mélanie
AU - Fairley, Christopher K.
AU - Garland, Suzanne M.
AU - Kahn, Jessica A.
AU - Kavanagh, Kimberley
AU - Markowitz, Lauri
AU - Pollock, Kevin G.
AU - Söderlund-Strand, Anna
AU - Sonnenberg, Pam
AU - Tabrizi, Sepehr N.
AU - Tanton, Clare
AU - Unger, Elizabeth
AU - Thomas, Sara L.
N1 - Publisher Copyright:
© 2016, Centers for Disease Control and Prevention (CDC). All rights reserved.
PY - 2016/10
Y1 - 2016/10
N2 - We analyzed human papillomavirus (HPV) prevalences during prevaccination and postvaccination periods to consider possible changes in nonvaccine HPV genotypes after introduction of vaccines that confer protection against 2 high-risk types, HPV16 and HPV18. Our meta-analysis included 9 studies with data for 13,886 girls and women ≤19 years of age and 23,340 women 20–24 years of age. We found evidence of cross-protection for HPV31 among the younger age group after vaccine introduction but little evidence for reductions of HPV33 and HPV45. For the group this same age group, we also found slight increases in 2 nonvaccine high-risk HPV types (HPV39 and HPV52) and in 2 possible high-risk types (HPV53 and HPV73). However, results between age groups and vaccines used were inconsistent, and the increases had possible alternative explanations; consequently, these data provided no clear evidence for type replacement. Continued monitoring of these HPV genotypes is important.
AB - We analyzed human papillomavirus (HPV) prevalences during prevaccination and postvaccination periods to consider possible changes in nonvaccine HPV genotypes after introduction of vaccines that confer protection against 2 high-risk types, HPV16 and HPV18. Our meta-analysis included 9 studies with data for 13,886 girls and women ≤19 years of age and 23,340 women 20–24 years of age. We found evidence of cross-protection for HPV31 among the younger age group after vaccine introduction but little evidence for reductions of HPV33 and HPV45. For the group this same age group, we also found slight increases in 2 nonvaccine high-risk HPV types (HPV39 and HPV52) and in 2 possible high-risk types (HPV53 and HPV73). However, results between age groups and vaccines used were inconsistent, and the increases had possible alternative explanations; consequently, these data provided no clear evidence for type replacement. Continued monitoring of these HPV genotypes is important.
UR - https://www.scopus.com/pages/publications/84988530527
U2 - 10.3201/eid2210.160675
DO - 10.3201/eid2210.160675
M3 - Article
C2 - 27648688
AN - SCOPUS:84988530527
SN - 1080-6040
VL - 22
SP - 1732
EP - 1740
JO - Emerging Infectious Diseases
JF - Emerging Infectious Diseases
IS - 10
ER -
